Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam versus meropenem for hospital-acquired pneumonia including ventilator-associated pneumonia
2012-004006-96Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2012
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Ceftazidime-avibactam arm with Meropenem arm (2 arms). Primary endpoints: Clinical cure at test of cure in clinically modified intent-to-treat population and Clinical cure at test of cure in clinically evaluable population. Started Dec 2012; status: completed.
02
Drugs
ceftazidime + avibactammeropenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2012-004006-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004006-96.